MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.18
+0.53
+3.62%
After Hours: 15.18 0 0.00% 16:01 05/26 EDT
OPEN
14.68
PREV CLOSE
14.65
HIGH
15.38
LOW
14.60
VOLUME
402.38K
TURNOVER
0
52 WEEK HIGH
22.71
52 WEEK LOW
13.27
MARKET CAP
853.61M
P/E (TTM)
102.85
1D
5D
1M
3M
1Y
5Y
Goldman Sachs Adjusts Price Target for Syndax Pharmaceuticals to $40 From $51, Retains Buy Rating
MT Newswires · 2d ago
Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, wil...
PR Newswire · 05/11 11:00
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 22:25
Syndax Pharmaceuticals GAAP EPS of -$0.63
Syndax Pharmaceuticals press release (NASDAQ:SNDX): Q1 GAAP EPS of -$0.63. Total operating expenses of $36.85M. Research and development expenses of $30.02M. For Q2: Research and development expenses are expected to
Seekingalpha · 05/09 20:15
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
Syndax Pharmaceuticals Q1 2022 Earnings Preview
Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$0.69 and the consensus Revenue Estimate is $2.56M
Seekingalpha · 05/08 21:35
Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results o...
PR Newswire · 05/02 11:00
More
No Data
Learn about the latest financial forecast of SNDX. Analyze the recent business situations of Syndax Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SNDX stock price target is 32.86 with a high estimate of 51.00 and a low estimate of 26.00.
High51.00
Average32.86
Low26.00
Current 15.18
EPS
Actual
Estimate
-0.120.481.071.67
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 178
Institutional Holdings: 52.86M
% Owned: 94.00%
Shares Outstanding: 56.23M
TypeInstitutionsShares
Increased
42
8.55M
New
30
3.10M
Decreased
34
3.61M
Sold Out
19
4.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Dennis Podlesak
President/Director
Briggs Morrison
Chief Executive Officer/Director
Michael Metzger
Senior Vice President/General Counsel/Secretary
Luke Albrecht
Senior Vice President
Michael Meyers
Chief Accounting Officer/Vice President
Alexander Nolte
Chief Scientific Officer
Peter Ordentlich
Other
Anjali Ganguli
Other
Catherine Madigan
Independent Director
Martin Huber
Independent Director
Jennifer Jarrett
Independent Director
Keith Katkin
Independent Director
Pierre Legault
Independent Director
William Meury
No Data
No Data
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule, and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer.

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.